2023-04-27 03:09:12
Samjin Pharmaceutical announced on the 27th that it obtained priority sale permission from the Ministry of Food and Drug Safety on the 21st following patent avoidance following a trial decision cited by the Intellectual Property Tribunal for a passive right scope confirmation trial on the 19th for the pulmonary arterial hypertension treatment ‘Maciten Tab (Macitentan)’. revealed
As a result, ‘Mashiten Chung’ will be able to conduct exclusive sales and marketing for 9 months after its release. Currently, it has started the release process to preoccupy the generic market quickly.
Pulmonary arterial hypertension is caused by an increase in blood pressure in the pulmonary artery, which supplies blood from the heart to the lungs, and is known to be an intractable disease that can cause right heart failure and sudden cardiac death.
In Korea, it is estimated that about 6,000 people are suffering from the disease due to the low awareness rate and treatment rate of the disease.
Among these treatments for pulmonary arterial hypertension, ‘Macitentan’, which is classified as an endothelin receptor antagonist, is currently widely used as a single or combination therapy, and its effectiveness has been verified.
According to data from IQVIA, a pharmaceutical market research institute, sales of Machitentan in the domestic pulmonary arterial hypertension treatment market were about 17 billion won as of last year.
“Mashiten Tab.’s low drug price compared to the original drug will be a new alternative that lowers the economic burden of patients suffering from diseases,” said Yu Jeong-min, PM of Samjin Pharmaceutical’s Mashiten Tab. I will wait,” he said.
In the future, Samjin Pharmaceutical plans to consolidate its position through clinical trials of its own products along with aggressive marketing of ‘Mashiten Tab.’
1682572736
#Samjin #Pharm #acquires #sell #Masiten #Tablets #treatment #pulmonary #arterial #hypertension